Clinical and virological characteristics of critically ill patients with influenza in France during the 2025/26 season, marked by the emergence of influenza A(H3N2) clade K Importance: Recent reports have highlighted an intense influenza activity related to the circulation of the influenza A(H3N2) subclade k variant. There is no data available on the impact of the emerge...

Happy to share our preprint “ICU patients with influenza during 2025–26 : a French nationwide cohort study”, conducted within the SEVARVIR consortium, supported and funded by ANRS-MIE.
Severe H3N2 in 25–26 (subclade K) did not worsen outcomes in ICU patients.

www.medrxiv.org/content/10.6...

Bonjour
Merci. Attention la grippe B Yamagata s’est probablement éteinte chez l’homme depuis quelques années (conséquences des restrictions post-emergence Covid)

How mRNA Vaccines Can Help Fight Cancer Turning "cold" tumors "hot"

How do mRNA vaccines help fight cancer?
A @nature.com paper today tells the story, one with big implications, as reviewed here
erictopol.substack.com/p/how-mrna-v...

Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections - npj Vaccines npj Vaccines - Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections

Not just shingles vaccine, but also RSV vaccine reduces the risk of dementia, which highlights the benefit of revving up the immune system in older individuals
www.nature.com/articles/s41...

A single shot of a flu drug could outperform vaccines—and protect for an entire season One injection of a long-lasting drug showed up to 76% efficacy in a large trial

In some good news- this is an interesting idea. Lencapavirification (yes I made that term up) of flu antivirals:

www.science.org/content/arti...

Details on the drug here.
www.nature.com/articles/s41...

Molecular characterization of RSV infections in elderly patients during the 2023/2024 season in the era of nirsevimab introduction RSV can cause severe infections in the elderly. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023/2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly.

Molecular characterization of RSV infections in elderly patients during the 2023/2024 season in the era of nirsevimab introduction

✅ Just Accepted
#IDSky